找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Virus Entry Inhibitors; Stopping the Enemy a Shibo Jiang,Lu Lu Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive l

[復(fù)制鏈接]
樓主: ACRO
41#
發(fā)表于 2025-3-28 16:50:19 | 只看該作者
Human Papillomavirus (HPV) Entry Inhibitors,eveloping new diagnostic and prognostic biomarkers and designing more effective targeted therapeutics and treatment strategies remains urgent. Numerous efforts have been made to design new drugs and vaccines to treat HPV infections. Due to the special HPV infection pathway, entry inhibitors to block
42#
發(fā)表于 2025-3-28 21:22:27 | 只看該作者
43#
發(fā)表于 2025-3-29 00:42:34 | 只看該作者
44#
發(fā)表于 2025-3-29 04:59:27 | 只看該作者
Endogenous Peptide Inhibitors of HIV Entry,ents and beyond. Finally, we provide examples for other endogenous peptides that may contribute to our innate immune defense against HIV-1 and other viral pathogens and offer prospects for preventive or therapeutic development.
45#
發(fā)表于 2025-3-29 08:17:59 | 只看該作者
Virus Entry Inhibitors: Past, Present, and Future,e prophylaxis, microbicides, and therapeutics. This chapter, as well as this book, provides more information on the development and modification of peptide-, small-molecule-, and protein-based virus entry inhibitors.
46#
發(fā)表于 2025-3-29 13:03:34 | 只看該作者
47#
發(fā)表于 2025-3-29 17:37:41 | 只看該作者
Coronavirus Entry Inhibitors,ses in viral entry, such as receptor binding, proteolytic activation of spike protein, or virus-cell membrane fusion. Coronavirus entry inhibitors, alone or in combination with other drugs, play important roles in the treatment of coronavirus diseases. Thus, we summarize and discuss the development of coronavirus entry inhibitors in this chapter.
48#
發(fā)表于 2025-3-29 19:49:19 | 只看該作者
Influenza Virus Entry inhibitors,trials, including small molecule, natural product, peptide-based entry inhibitors, and other types of entry inhibitors, herein discussing some open questions. Assay methods of influenza virus entry inhibitors are also outlined.
49#
發(fā)表于 2025-3-30 02:32:43 | 只看該作者
50#
發(fā)表于 2025-3-30 04:48:46 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-16 07:50
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
武宣县| 宜州市| 南皮县| 陆丰市| 遂宁市| 卫辉市| 湖州市| 高唐县| 吉隆县| 乐都县| 台北县| 广平县| 民乐县| 临澧县| 仙游县| 新乐市| 泽库县| 揭东县| 峨山| 宜丰县| 洪洞县| 琼海市| 常熟市| 伊宁市| 周宁县| 勐海县| 乌拉特前旗| 潍坊市| 翼城县| 宁城县| 濉溪县| 永川市| 和硕县| 郎溪县| 沅江市| 简阳市| 台北县| 新闻| 三河市| 惠东县| 宁夏|